Mersana Therapeutics Inc Growth Comparisons

Select each growth Category to receive further Information

Select the Comparisons :

Growth Rates ▼

Select the Ratio:

None▼

Growth Rates ▼

None▼

Download as CSV

MRSN Revenue Growth Rate Comparisons	Company	Industry	Sector	S&P 500
Y / Y Revenue Growth (Q2 MRQ)	33.28 %	8.14 %	5.99 %	4.7 %
Q / Q Revenue Growth (Q2 MRQ)	10.97 %	9.68 %	5.87 %	4.11 %
Y / Y Revenue Growth (for 12 months ending Q2 TTM)	16.14 %	8.96 %	5.75 %	%
Sequential Revenue Growth (for 12 months ending Q2 TTM)	2.24 %	2 %	1.39 %	1.17 %
Revenue 5 Year Average Growth	-0.78 %	8.99 %	8.21 %	7.56 %

MRSN's Growth Comparisons in II. Quarter 2025

With 33.28% year on year Revenue increase in the second quarter 2025, Mersana Therapeutics Inc outperformed the 8.14% growth in the Major Pharmaceutical Preparations industry, and 5.99% growth in the Healthcare sector. Above the average sales gains in the Healthcare and in the Major Pharmaceutical Preparations industry, helped to elevate overall market growth to 4.7%.

Top-line improved by 10.97% from the first quarter. Looking into annual sales rise of -0.78%, and S & P 500's average yearly sales growth is 7.56% over the five years, including only Businesses with the second quarter 2025 Results. Mersana Therapeutics Inc grew less than the market.

MRSN Growth Rates by Company's Segments

Segment Name	Y / Y	Sequential
Reportable Segment	33.28 %	10.97 %
Total	33.28 %	10.97 %

Growth Rates of MRSN's Income in the second quarter 2025

MRSN Operating Income Growth Rates Comparisons	Company	Industry	Sector	S&P 500
Y / Y Operating Income Change (Q2 MRQ)	-	68.15 %	57.81 %	10.32 %
Sequential Operating Income Change (Q2 MRQ)	-	21.2 %	15.93 %	4.92 %
Y / Y Operating Income Growth (Q2 TTM)	-	120.39 %	69.09 %	3.22 %
Sequential Operating Income Growth (Q2 TTM)	-	15.3 %	12.78 %	0.95 %
Operating Income 5 Year Avg. Change	-	-2.03 %	-2.02 %	9.12 %

Income from Cont. Ops. Growth Rates Comparisons	Company	Industry	Sector	S&P 500
Y / Y Income from Cont. Ops. Change (Q2 MRQ)	-	104.68 %	161.62 %	6.6 %
Sequential Income from Cont. Ops. Change (Q2 MRQ)	-	0.56 %	7.49 %	6.18 %
Y / Y Income from Cont. Ops. Change (Q2 TTM)	-	182.01 %	167.85 %	9.77 %
Sequential Income from Cont. Ops. Change (Q2 TTM)	-	19.35 %	24.84 %	1.93 %
Income from Cont. Ops. 5 Year Avg. Change	-	-4.01 %	-9.4 %	9.11 %

MRSN Net Income Growth Rates Comparisons	Company	Industry	Sector	S&P 500
Y / Y Net Income Growth (Q2 MRQ)	-	105.73 %	152.67 %	8.18 %
Q / Q Net Income Growth (Q2 MRQ)	-	1.2 %	6.95 %	6.45 %
Y / Y Net Income Change (Q2 TTM)	-	51.6 %	70.08 %	9.28 %
Sequential Net Income Change (Q2 TTM)	-	19.6 %	23.27 %	2.32 %
Net Income 5 Year Avg. Growth	-	-5 %	-8.86 %	8.67 %

MRSN's EPS Growth Rates

EPS from Cont. Ops. Growth Rates Comparisons	Company	Industry	Sector	S&P 500
Y / Y EPS from Cont. Ops. Change (Q2 MRQ)	-	98.43 %	161.62 %	6.6 %
Sequential EPS from Cont. Ops. Change (Q2 MRQ)	-	0.08 %	7.49 %	6.18 %
Y / Y EPS from Cont. Ops. Change (Q2 TTM)	-	-	-	-
Sequential EPS from Cont. Ops. Change (Q2 TTM)	-	-	-	-37.11 %
EPS from Cont. Ops. 5 Year Avg. Growth	-	-12.1 %	-9.4 %	9.11 %

MRSN EPS Net Growth Rates Comparisons	Company	Industry	Sector	S&P 500
Y / Y EPS Net Growth (Q2 MRQ)	-	99.45 %	152.67 %	9.11 %
Q / Q EPS Net Growth (Q2 MRQ)	-	0.71 %	6.95 %	6.45 %
Y / Y EPS Net Change (for 12 months ending Q2 TTM)	-	-	-	-40.33 %
Sequential EPS Net Change (for 12 months ending Q2 TTM)	-	-	-	-37.11 %
EPS Net 5 Year Avg. Change	-	-5 %	-8.86 %	8.67 %

Mersana Therapeutics Inc reported bottom-line of $ -4.87 in the second quarter, compare to $ -0.20 in the same quarter a year ago. Major Pharmaceutical Preparations industry grew by 99.45%, while Healthcare sector increased by 152.67%, and overall market improved by 8.18%.

The bottom-line improved by 10.97% from the first quarter. Looking into annual income per share rise of -0.78%, and S & P 500's average yearly income per share growth is 8.67% over the five years, including only Businesses with the second quarter 2025 earnings reports. Mersana Therapeutics Inc grew less than the market.

MRSN Cash Flow Growth Rates

Free Cash Flow Growth Rates	Company	Industry	Sector	S&P 500
Y / Y Free Cash Flow Change (Q2 MRQ)	-	54.6 %	27 %	-8.64 %
Sequential Free Cash Flow Change (Q2 MRQ)	-	42.43 %	48.41 %	1421.99 %
Y / Y Free Cash Flow Change (Q2 TTM)	-	22.39 %	19.3 %	-5.86 %
Sequential Free Cash Flow Change (Q2 TTM)	-	7.24 %	4.11 %	-0.64 %
Free Cash Flow 5 Year Avg. Change	-	8.78 %	4.62 %	8.25 %

Net Cash Flow Growth Rates	Company	Industry	Sector	S&P 500
Y / Y Net Cash Flow Change (Q2 MRQ)	-	-	-	-
Sequential Net Cash Flow Change (Q2 MRQ)	-	-	-	-
Y / Y Net Cash Flow Change (Q2 TTM)	-	-	-	-
Sequential Net Cash Flow Change (Q2 TTM)	-	-	-	-
Net Cash Flow 5 Year Avg. Change	-	-31.61 %	-19.62 %	0.44 %

Capital Expenditures	Company	Industry	Sector	S&P 500
Y / Y Capital Expenditures Change (Q2 MRQ)	-	14.05 %	3.21 %	17.12 %
Sequential Capital Expenditures Change (Q2 MRQ)	-	-0.2 %	2.58 %	10.67 %
Y / Y Capital Expenditures Change (Q2 TTM)	-	11.97 %	7.51 %	16.6 %
Sequential Capital Expenditures Change (Q2 TTM)	-	3.56 %	0.68 %	4.06 %
Capital Expenditures 5 Year Avg. Change	-26.25 %	9.47 %	8.03 %	7.55 %

Note
To view Detail Information & Trends click on Individual Category. Example: Y / Y Revenue Change (MRQ) or To see Industry, Sector or S&P 500 Performance, click on each Category respectivly, on the top of the Table. Example: Industry Sector S&P 500 For explanation of terms visit: Glossary

Valuation Comparisons

Management Effectiveness

Financial Strength

Efficiency

Dividend Comparisons

Help

About us

Terms of Use

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.